A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Clindamycin Phosphate (1.2%) And Tretinoin (0.025%) Topical Gel (Actavis Mid-Atlantic Llc) To Ziana (Clindamycin Phosphate 1.2% And Tretinoin 0.025%) Gel (Medicis, The Dermatology Company) And Both Active Treatments To Clindamycin Phosphate (1.2%) And Tretinoin (0.025%) Topical Gel Placebo (Actavis Mid-Atlantic Llc) In The Treatment Of Mild To Severe Acne Vulgaris.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Clindamycin/tretinoin (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- 17 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by Clinical Trials Registry - India.
- 10 Dec 2010 Biomarkers information updated
- 09 Dec 2010 Planned end date (Oct 2010) added as reported by ClinicalTrials.gov.